✦ LIBER ✦

Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up

✍ Scribed by Rakesh Popat; Heather E. Oakervee; Simon Hallam; Nicola Curry; Liz Odeh; Nicola Foot; Dixie-Lee Esseltine; Mary Drake; Curly Morris; Jamie D. Cavenagh

Book ID: 108675616
Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 125 KB
Volume: 141
Category: Article
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.2008.06997.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety and efficacy of bortezomib and me

Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up

✍ James R. Berenson; Hank H. Yang; Robert A. Vescio; Youram Nassir; Russell Mapes; 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 164 KB

Superior overall survival of patients wi

Superior overall survival of patients with myeloma achieving very good partial response or better to initial treatment with bortezomib, pegylated liposomal doxorubicin, and dexamethasone, predicted after two cycles by a free light chain- and M-protein-based model: extended follow-up of a phase II trial

✍ Dytfeld, Dominik; Griffith, Kent A.; Friedman, Judah; Lebovic, Daniel; Harvey, C 📂 Article 📅 2011 🏛 Informa plc 🌐 English ⚖ 618 KB